International Stem Cell Corporation
This article was originally published in The Rose Sheet
Executive SummaryISCO says its subsidiary Lifeline Skin Care is targeting late summer or fall of 2010 for a line of three cosmetic products based on the firm's stem cell technology. "Early human trials show that these cosmetic products moisturize skin and strongly indicate the ability to decrease the depth of wrinkles and provide factors that lead to anti-aging effects," according to April 8 release. The forthcoming line combines extracts from human parthenogenetic stem cells (hpSC) with a vitamin complex and relies on nanotechnology to deliver active ingredients to damaged skin, says Oceanside, California-based ISCO, which has partnered with fellow Californian Cosmetic Enterprises, Ltd. to formulate and package its offering. Company notes that use of hpSC "avoid[s] critical ethical issues by eliminating the need to use fertilized embryos and can be immune-matched to large segments of the population." "The Rose Sheet" spoke with ISCO Chairman Kenneth C. Aldrich in April of last year (1"The Rose Sheet" April 27, 2009)
You may also be interested in...
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products
Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.